FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology The agreement enables drug developers to….
MILAN (Italy) and MADISON (Wis., USA) – October 6, 2020 – Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process…..
Madison, Wis./ Irvine, Calif., March 31, 2020— FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, and FUJIFILM Irvine Scientific, Inc., a leader in cell culture media, announced that beginning April 1, 2020 iCell® products will be sold by the FUJIFILM “Discovery Research” organization (part of FUJIFILM Irvine Scientific).
Strengthening fundamental research capabilities in the areas of gene therapy, cell therapy and regenerative medicine applications, and promoting industry-leading advanced research by incorporating cutting-edge technologies in the U.S. and fusing the group technologies
Tokyo, December 5, 2019― FUJIFILM Corporation (President: Kenji Sukeno) announced that it has begun full-scale research activities to advance the field of translational research for biotherapeutics at its newly established “Bio Science & Engineering Laboratories U.S.A.” (“US Bio Center”) located in Madison, Wisconsin. The goal of the Fujifilm US Bio Center will be to further strengthen its fundamental research efforts to support the broad goals of Fujifilm in the areas gene therapy, cell therapy and regenerative medicine applications.